InvestorsHub Logo
Followers 4
Posts 479
Boards Moderated 0
Alias Born 01/03/2015

Re: None

Tuesday, 10/15/2019 9:18:38 PM

Tuesday, October 15, 2019 9:18:38 PM

Post# of 403033

Hoping we get an update on K soon. Per company...
As we continue to advance the clinical development of our Brilacidin programs in Oral Mucositis and Inflammatory Bowel Disease, the Company concurrently plans to devote resources to Kevetrin, including completing remaining bridging toxicology work toward developing Kevetrin in oral form. An orally-delivered Kevetrin would likely enhance the therapeutic benefits based on its pharmacokinetics, and broaden its market potential by meeting cancer patient’s strong preference for oral meds.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News